



**Date: 31st July, 2025**

**To,**  
**BSE Ltd,**  
**Listing Department,**  
Phiroze Jeejeebhoy Towers,  
Dalal Street - Fort,  
Mumbai – 400 001

**Scrip Code: 539730**

Dear Sir/ Madam,

**Sub.: Press Release issued by Fredun Pharmaceuticals Limited**

Please find enclosed Press Release issued by Fredun Pharmaceuticals Limited Stating  
“**Fredun Pharmaceuticals Net Profit Rises 64% YoY in Q1 F26**”.

Kindly take the same on your records and acknowledge the receipt.

Thanking you,

Yours truly,

For **Fredun Pharmaceuticals Limited**

**FREDUN NARIMAN MEDHORA**  
**MANAGING DIRECTOR**  
**DIN: 01745348**

**Encl: A/a**





## Fredun Pharmaceuticals Net Profit Rises 64% YoY in Q1 FY26

**Mumbai – July 31, 2025:** – Fredun Pharmaceuticals Limited (BSE – FREDUN | 539730), is one of the Leading Pharmaceuticals Formulation manufacturing companies in India. Diversified into Generics, Cosmeceuticals, Nutraceuticals, Mobility and Animal Healthcare Products, has reported its Unaudited financials for Q1 FY26.

### Key Financial Highlights

Particulars (₹ Cr)	Q1 FY26	Q1 FY25	YoY
Total Income	119.86	78.81	52.08%
EBITDA	16.99	10.48	62.15%
EBITDA Margin (%)	14.18	13.30	88 BPS
Net Profit	6.77	4.13	63.82%
Net Profit Margin (%)	5.64	5.24	40 BPS
Diluted EPS (₹)	14.33	8.79	63.03%

**Commenting on the financial performance Mr. Fredun Medhora, Managing Director, said** “We are pleased to report a strong start to FY26 with a significant year-on-year growth in net profit and healthy improvement across all key financial metrics. Our performance reflects the successful execution of our growth strategy and the continued demand for our diversified portfolio across domestic and international markets. Our generics portfolio continues to strengthen, with over 1,200 products currently under registration. **Our current order book stands at over ₹200 crore**, providing strong revenue visibility and momentum for the upcoming quarters.

We have entered the organized pet care market with the acquisition of a controlling stake in One Pet Stop through our subsidiary FRPL, giving us access to a loyal customer base and a tech-enabled, doorstep grooming service. This move complements our premium Freossi pet care range and strengthens our vision to grow as a holistic player in India’s rapidly expanding pet wellness space.

The pharmaceutical and healthcare industry continues to see robust demand driven by increasing health awareness, focus on affordable care, and supportive regulatory frameworks. With our growing presence in generics, cosmeceuticals, nutraceuticals, mobility aids, and animal health products, we are well-positioned to capitalize on these opportunities. Looking ahead, we remain committed to enhancing value through consistent performance, product innovation, and expanding our global reach.”

## Q1 FY26 Key Business Highlights

<b>Upgrade in Credit Rating</b>	<ul style="list-style-type: none"><li>• <b>Rating Upgrade:</b><ul style="list-style-type: none"><li>○ Long-term rating upgraded to IVR BBB/Stable (from IVR BBB-/Stable)</li><li>○ Assigned IVR BBB/Stable / IVR A3+ for long/short-term facilities</li></ul></li><li>• <b>Total amount rated:</b> ₹139.64 Cr</li></ul>
<b>Acquisition of One Pet Stop</b>	<ul style="list-style-type: none"><li>• <b>Entity Involved:</b> Fredun Retail Pvt. Ltd. (FRPL), a wholly owned subsidiary.</li><li>• <b>Acquisition:</b> FPRL acquires controlling stake in One Pet Stop Pvt. Ltd.</li></ul>

## About Fredun Pharmaceuticals Limited


Fredun Pharmaceuticals Limited, healthcare and pharmaceuticals company offer a range of products, including antihypertensives, antidiabetic, antiretroviral drugs (ARVs) and narcotics. It is also engaged in the manufacturing of dietary/herbal supplements, nutraceuticals, cosmeceuticals, and other healthcare products along with animal healthcare products. With such a diverse range of products, the Company's objective is to be a holistic healthcare provider. The Company primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries and Latin America.

In the FY25, Fredun reported total revenues of ₹ 456 Cr, with an EBITDA of ₹ 55 Cr and a PAT of ₹ 21 Cr.

## Disclaimer

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

## For Further Information Please Contact Corporate Communication Advisor

	<b>Kirin Advisors Private Limited</b> Sunil Mudgal - Director <a href="mailto:sunil@kirinadvisors.com">sunil@kirinadvisors.com</a> +91 98692 75849 <a href="http://www.kirinadvisors.com">www.kirinadvisors.com</a>
---	---